Abivax SA American Depositary Shares (ABVX)vsBeiGene, Ltd. (ONC)
ABVX
Abivax SA American Depositary Shares
$118.64
+2.32%
HEALTHCARE · Cap: $10.02B
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 124472% more annual revenue ($6.13B vs $4.92M). ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).
ABVX
Avoid33
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABVX.
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.2% year-over-year
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Trading at 18.8x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVX
The strongest argument for ABVX centers on Revenue Growth. Revenue growth of 35.2% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : ABVX
The primary concerns for ABVX are Price/Book, EPS Growth, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
ABVX profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ABVX is growing revenue faster at 35.2% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 33/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abivax SA American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in advanced clinical trials targeting ulcerative colitis, utilizing a novel approach that integrates antibody-mediated therapies with proprietary compounds. Backed by a robust pipeline and an experienced scientific team, Abivax is strategically positioned to meet substantial unmet medical needs, making it an attractive prospect for institutional investors aiming to engage with the growing immunotherapy landscape.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?